Evaluation of the frequency of non-motor symptoms of Parkinson’s disease in adult patients with Gaucher disease type 1
Authors:
- Matheus V. M. B. WilkeMWMatheus V. M. B. Wilke
- Alícia D. DornellesADAlícia D. Dornelles
- Artur S. SchuhASArtur S. Schuh
- Filippo P. VairoFVFilippo P. Vairo
- Suelen P. BasgaluppSBSuelen P. Basgalupp
- Marina SiebertMSMarina Siebert
- Tatiele NalinTNTatiele Nalin
- Otavio B. PiltcherOPOtavio B. Piltcher
- Ida V. D. SchwartzISIda V. D. Schwartz
Open Access
- 10 May 2019
- journal article
- research article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 14 (1) , 1-7
Abstract
Gaucher disease (GD) is caused by deficiency of beta-glucocerebrosidase (GCase) due to biallelic variations in the GBA1 gene. Parkinson’s disease (PD) is the second most common neurodegenerative condition. The classic motor symptoms of PD may be preceded by many non-motor symptoms (NMS), which include hyposmia, rapid eye movement (REM) sleep behavior disorder, constipation, cognitive impairment, and depression. Population studies have identified mutations in GBA1 as the main risk factor for idiopathic PD. The present study sought to evaluate the prevalence of NMS in a cohort of patients with GD type 1 from Southern Brazil. This is an observational, cross-sectional study, with a convenience sampling strategy. Cognition was evaluated by the Montreal Cognitive assessment (MoCa), daytime sleepiness by the Epworth Scale, depression by the Beck Inventory, constipation by the Unified Multiple System Atrophy Rating Scale, and REM sleep behavior disorder by the Single-Question Screen; hyposmia by the Sniffin’ Sticks. Motor symptoms were assessed with part III of the Unified Parkinson’s Disease Rating Scale. All patients were also genotyped for the GBA1 3′-UTR SNP (rs708606). Twenty-three patients (female = 13; on enzyme replacement therapy = 21, substrate reduction therapy = 2) with a mean age of 41.45 ± 15.3 years (range, 22–67) were included. Eight patients were found to be heterozygous for the 3′-UTR SNP (rs708606). Fourteen patients (8 over age 40 years) presented at least one NMS; daytime sleepiness was the most frequent (n = 10). Two patients (aged 63 and 64, respectively) also presented motor symptoms, probably drug-related. NMS were prevalent in this cohort. We highlight the importance of a multidisciplinary follow-up focusing on earlier diagnosis of PD, especially for patients with GD type 1 over the age of 40.Keywords
This publication has 21 references indexed in Scilit:
- Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration ProcessCellular and Molecular Neurobiology, 2018
- A Review of Gaucher Disease Pathophysiology, Clinical Presentation and TreatmentsInternational Journal of Molecular Sciences, 2017
- New concepts in the pathogenesis and presentation of Parkinson’s diseaseClinical Medicine, 2016
- Prodromal Clinical Markers of Parkinson disease in Gaucher Disease IndividualsEuropean Neurology, 2016
- The relationship between glucocerebrosidase mutations and Parkinson diseaseJournal of Neurochemistry, 2016
- Glucocerebrosidase and Parkinson disease: Recent advancesMolecular and Cellular Neuroscience, 2015
- The emergence of Parkinson disease among patients with Gaucher diseaseBest Practice & Research Clinical Endocrinology & Metabolism, 2015
- Evolution of Prodromal Clinical Markers of Parkinson Disease in aGBAMutation–Positive CohortJAMA Neurology, 2015
- Brain-derived neurotrophic factor expression increases after enzyme replacement therapy in Gaucher diseaseJournal of Neuroimmunology, 2015
- Hyposmia and cognitive impairment in Gaucher disease patients and carriersMovement Disorders, 2012